| Subject: | FDA Issues Notice of Revisions to Warnings for the Drug Aranesp |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 24 Jan 2005 - 10:00 am |
| The FDA and manufacturer Amgen Inc., notified healthcare professionals about revisions to the warnings and precaution sections of prescribing information for the drug Aranesp (darbepoetin alfa). Aranesp is utilized in the treatment of kidney disease and chemotherapy related anemia. Aranesp stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. In responding to hypoxia, Aranesp increases red blood cell (RBC) production. The FDA and Amgen, Inc. note that there has been an... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
